Johnson & Johnson (JNJ) MedTech, Tuesday announced results from the VARIPURE substudy of SECURE, evaluating the VARIPULSE Platform in pulsed field ablation procedures for atrial fibrillation or AF.
The real world data showed a strong safety profile, high acute effectiveness and procedural efficiency among the participants with a 0.6 percent primary adverse event rate and a 99.7 percent acute PVI rate along with high adherence to the recommended ablation workflow.
The company added that the consistency and scale of these results reinforce PFA as a transformative option for AF care.
Moreover, the company will continue collaborating with the clinical community to expand real-world evidence around the VARIPULSE Platform and accelerate patient-centered innovation in atrial fibrillation care.
In the pre-market hours, JNJ is trading at $177.18, up 0.02 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.